- Home
- STK vs CELC Comparison
STK vs CELC Comparison
Compare STK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- CELC
- Stock Information
- Founded
- STK 2009
- CELC 2011
- Country
- STK United States
- CELC United States
- Employees
- STK N/A
- CELC N/A
- Industry
- STK Investment Managers
- CELC Medical Specialities
- Sector
- STK Finance
- CELC Health Care
- Exchange
- STK Nasdaq
- CELC Nasdaq
- Market Cap
- STK 545.5M
- CELC 612.8M
- IPO Year
- STK N/A
- CELC 2017
- Fundamental
- Price
- STK $31.94
- CELC $15.10
- Analyst Decision
- STK
- CELC Strong Buy
- Analyst Count
- STK 0
- CELC 6
- Target Price
- STK N/A
- CELC $28.67
- AVG Volume (30 Days)
- STK 38.2K
- CELC 327.3K
- Earning Date
- STK 01-01-0001
- CELC 11-11-2024
- Dividend Yield
- STK 6.60%
- CELC N/A
- EPS Growth
- STK N/A
- CELC N/A
- EPS
- STK N/A
- CELC N/A
- Revenue
- STK N/A
- CELC N/A
- Revenue This Year
- STK N/A
- CELC N/A
- Revenue Next Year
- STK N/A
- CELC N/A
- P/E Ratio
- STK N/A
- CELC N/A
- Revenue Growth
- STK N/A
- CELC N/A
- 52 Week Low
- STK $24.95
- CELC $8.39
- 52 Week High
- STK $34.31
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- STK 49.22
- CELC 41.93
- Support Level
- STK $30.88
- CELC $14.58
- Resistance Level
- STK $32.27
- CELC $16.00
- Average True Range (ATR)
- STK 0.60
- CELC 0.71
- MACD
- STK -0.00
- CELC -0.09
- Stochastic Oscillator
- STK 41.54
- CELC 19.08
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.